Tildrakizumab for Moderate-to-Severe Plaque Psoriasis Tildrakizumab for Moderate-to-Severe Plaque Psoriasis

Review the latest clinical studies on tildrakizumab, a promising new monoclonal antibody targeting IL-23p19, for patients with moderate-to-severe chronic plaque psoriasis.Skin Therapy Letter
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news